In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates | Zendy

Robert C. Owens | Zendy; Mary Anné Banevicius | Zendy; David P. Nicolau | Zendy; C H Nightingale | Zendy; Richard Quintiliani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates

Author(s) -

Robert C. Owens,

Mary Anné Banevicius,

David P. Nicolau,

C H Nightingale,

Richard Quintiliani

Publication year - 1997

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.41.11.2586

Subject(s) - ticarcillin , piperacillin , tobramycin , microbiology and biotechnology , mezlocillin , acinetobacter , tazobactam , cefoperazone , piperacillin/tazobactam , aminoglycoside , ceftazidime , biology , enterobacter cloacae , pseudomonas aeruginosa , antibiotics , imipenem , enterobacteriaceae , gentamicin , bacteria , escherichia coli , antibiotic resistance , biochemistry , genetics , gene

The microdilution checkerboard technique was utilized to distinguish synergistic activity between tobramycin and four beta-lactams: piperacillin-tazobactam, ticarcillin-clavulanate, ceftazidime, and ceftriaxone. Beta-lactam-aminoglycoside combinations were tested against 75 clinical isolates of Pseudomonas aeruginosa, Acinetobacter baumanii, Citrobacterfreundii, Serratia marcescens, and Enterobacter cloacae. Despite in vitro susceptibilities, all isolates demonstrated either synergism or indifference; no antagonism was observed. Against pathogenic gram-negative nosocomial isolates, a greater percentage of synergy was consistently observed with combination regimens containing tobramycin and piperacillin-tazobactam or ticarcillin-clavulanate than with the cephalosporin-containing regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research